The AMSBIO Cultrex® 3D Culture Cell Harvesting Kit is based on a non-enzymatic approach that prevents biochemical degradation during processing and overcomes the problems associated with extracting cells from 3D culture in BME or Laminin I.
The quality of the harvested cells is ideal for Western blotting and RNA and DNA analysis. In 3D culture, cells are grown in a microenvironment of specialized proteins that mimics in vivo conditions and allows the cells to organise into complex structures rather than uniform monolayers.
This new kit provides an optimised and standardised solution for the isolation and normalization of cell lysates from 3D Culture Matrix, BME or Laminin I for subsequent biochemical analysis.
3D Cultures exhibit cellular behaviours and morphologies similar to those seen in vivo; however, the adaptation of these models for studying biochemical processes has been impeded by the challenge of separating intact or 3D grown cells from extracellular proteins comprising the 3D matrix.
Commonly, proteases are employed to degrade these extracellular proteins; however, proteases also degrade proteins on the cell surface, and protease activity may carry over into lysate preparations. Non-enzymatic methodologies have also been described for depolymerising extracellular matrix proteins, although the implementation of these protocols remains problematic for some researchers.
Designed for efficient, small-scale purification and screening of histidine-tagged proteins from different sources.
His Mag Sepharose Ni products are magnetic beads designed for efficient, small-scale purification/screening of histidine-tagged proteins from different sources. Histidine-tagged proteins are captured using immobilized nickel ions followed by collection of the beads using a magnetic device. You can use magnetic beads to simplify sample handling during small-scale purification.
His Mag Sepharose Ni delivers:
High-capacity small-scale purification of histidine-tagged proteins from different sources
High purity and yield
Easy parallel screening of histidine-tagged proteins with high repeatability
Scalability—Simple capture of histidine-tagged proteins from small or large sample volumes (low microliter to milliliter scale)
The beads are available in three pack sizes: 2 × 1 ml 5% medium slurry, 5 × 1 ml 5% medium slurry, and 10 × 1 ml 5% medium slurry—a 1 ml 5% medium slurry is the same as 50 μl sedimented medium. A 1 ml medium slurry is sufficient for 5 purification runs according to the recommended protocol.
Together with MagRack 6, a separation tool for handling the beads in microcentrifuge tubes, up to six samples can be processed in parallel. You can easily screen a larger number of samples in parallel with high throughput on a robotic device.
The magnetic bead format has excellent properties for small-scale experiments. The high density of the beads allows rapid capture by magnetic devices while the visibility of the beads ensures reliable collection of the bound histidine-tagged proteins in the purification procedure. The characteristics of the media are summarized in Table 1. All the products are provided with protocols optimized for purification of histidine-tagged proteins.
Tabel 1. Characteristics of His Mag Sepharose Ni
Matrix: Highly crosslinked spherical agarose (Sepharose) including magnetite
Metal icon capacity: 21µmol Ni2+/ml medium
Binding capacity: approx. 50mg histidine-tagged protein/ml medium (approx. 500µg/purification run)
Particle size: 37 to 100µm
Working temperature: Room temperature and + 4ºC
Storage solution: 20% ethanol, 5% medium slurry
Storage temperature: Room temperature
GE Healthcare Europe GmbH
Dr. Michael Walther EMEA Marketing Manager Electrophoresis
T + 49 2293 816 749 M + 49 173 574 9413 F + 49 5564 204 593
To fulfill its responsibility towards the consumer, BIOTECON Diagnostics decided to develop high-quality detection kits for food allergens.
To fulfill its responsibility towards the consumer, BIOTECON Diagnostics decided to develop high-quality detection kits for food allergens. Therewith, the well-known and respected spectrum offoodproof® real-time PCR kits is extended by another interesting product division.
The first allergen kits that will be launched by the company from Potsdam, Germany, are the foodproof® Celery Detection Kit and the foodproof® Gluten Detection Kit. More allergen kits for the detection of soy, peanut and hazelnut will follow soon. In combination with the foodproof® Sample Preparation Kit III for theextraction of plant DNA, this kits allows simple and safe detection of allergens in all kind of foods. Depending on the source of literature the prevalence of food allergies is between 2 – 4 % for adults and 4 -8% for children.
The foodproof® Sample Preparation Kit III allows the extraction of highly purified DNA even from complex foods or processed matrices. To validate the foodproof® Allergen Detection Kits final products, raw materials and swab samples have been successfully tested. The kit cannot be only used for foods, finished products and raw materials, but also for cleaning validations. In addition, BIOTECON Diagnostics has developed a standardized reference material, Allergen RM 800, to create a standard curve for exact quantification.
More allergen kits for the detection of mustard, sesame, lupine and crustacean will be developed next year. Also it is planned to develop multiplex kits, to detect up to three different allergen-parameters within one reaction.
Food allergens became more important, because the frequency in the population has grown in the last decades. The reasons are still not totally clear; often it is credited to changing environmental influences and diets. Even the smallest amounts of allergens can cause severe allergic reactions up to life-threatening symptoms. For the consumer, the only protection is avoidance. According to EU-regulation 2007/68/EG 14, different allergenic ingredients have to be labeled in Europe on the products. Until now there is no threshold value in Europe or elsewhere. Therefore, the zero tolerance rule applies, even foods that only contain traces of allergens have to be labeled accordingly.
Dr. Kornelia Berghof-Jäger, Chief Executive Officer (CEO) of the Germany-based corporation BIOTECON Diagnostics therefore announced that „the expansion of our product portfolio by test kits for the detection of food allergens is a consequent continuation of our strategy to cover all aspects of food safety diagnostics bymolecular methods.“
„The new product line allows the users of our foodproof® system to enter new markets with the existing laboratory equipment without any additional financial investments.” emphasizes Alois Schneiderbauer, Chief Business Officer (CBO) of BIOTECON Diagnostics stated.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications.
The new PBK9 and PFK9 Weighing Platforms provide the rugged and reliable operation customers have come to expect from METTLER TOLEDO, paired with advanced technology for high-precision weighing.
Benefits of PBK9 and PFK9 Weighing Platforms include:
Outstanding accuracy: The platforms are ideally suited for all weighing processes in which quality is critical and tolerances need to be minimized.
Reliable performance: The platforms notify the operator when recalibration or adjustments are necessary due to environmental changes.
Easy maintenance: Automated calibration with a built-in calibration weight and plug-in cables allow for easy maintenance.
Versatile and Robust: The robust load cell with integrated overload protection and IP66/IP68 ingress protection makes the platforms suitable for a variety of challenging environments including wet areas, locations with heavy dust or workplaces that need regular cleaning.
The PBK9 and PFK9 Weighing Platforms virtually eliminate the impact of environmental interferences that cause errors and result in wasted ingredients or rejected batches. Advanced Monobloc and filter technology guarantees the highest precision and reliability possible.
In addition, the PBK9 and PFK9 weighing platforms are excellent standalone solutions and they also operate well as components in applications ranging from counting and formulating to filling. PBK9 and PFK9 Weighing Platforms offer multiple options, including mild, galvanized or stainless-steel for applications in wet, dusty, harsh or hazardous environments. Nine sizes and twelve capacities from 0.6 kilograms to 3 tons with resolutions up to 750,000 divisions respectively 30,000e (legal for trade) are available. All platforms can be connected to numerous METTLER TOLEDO terminals or directly connected to a control system.
From basic label design and printing to advanced import and editing options, LabelMark software improves the label-making experience for the electrical, industrial, aerospace, laboratory and telecom industries.
New LabelMark™ 6 software takes the hassle out of designing and printing labels. With an improved user interface and app-based navigation combined with Brady’s proven interactive label creation and single-click importing and serialization, you have high performance label printing that has never been easier.
Label Printing with an improved user interface:
Easy-to-use apps for creating wire harness, control panel and laboratory labels
Insert and edit AutoCAD layers, area of interests or entire files
Automatically repeat text on multiple lines of a label with LabelMark wire marker tool
Multi-label view for true representation of label formats
Adjust each individual label’s length in your print file
Quickly import data onto a label from an external data source
One-step serialization of data
“Check error” function to locate any import errors in prior to printing
Assign label materials to a specific printer for dedicated printing
Manage multiple files in a single job by grouping wire markers, push buttons, rating plates, and terminal block labels into one job file
Bi-directional communication with the IP, BMP®41, BMP®51,BMP®53, BMP®71 and BBP®33 printer series for automatic label format loading
The BioBLU 0.3f and BioBLU 1f Single-use Vessels allow microbial process development at the highest level.
The BioBLU 0.3f and BioBLU 1f Single-use Vessels allow microbial process development at the highest level. These rigid wall stirred-tank single-use vessels have been specifically designed for high cell density fermentation with bacteria, fungi and yeast. BioBLU f vessels can be used with the Eppendorf DASbox® and DASGIP® Parallel Bioreactor Systems.
Compared to cell culture applications, fermentation processes require much higher kLa values for proper mass transfer as well as suitable heating and cooling options. Proven stirred-tank design, powerful overhead drives featuring Rushton-type impellers and innovative baffles for cooling make the BioBLU f vessels achieve these demands.
Reliable scalability through industrial design
Sealed magnetic overhead drives with encapsulated bearings and Rushton-type impellers for excellent mixing
High performance mass & heat transfer suitable for high cell density fermentation
Minimal set-up times and most easy handling
Liquid-free Peltier exhaust condenser
All wetted materials animal component free and USP Class VI certified
Working volumes: 65 – 250 mL (BioBLU 0.3f) and 250 mL – 1.25 L (BioBLU 1f)
Combine the advantages of single-use bioreactor technology with the reliable performance of conventional glass or stainless steel bioreactors for your fermentation – Discover the Eppendorf BioBLU f product line: www.eppendorf.com/BioBLUf
GATC Biotech, a leading provider of advanced genome analysis and diagnostic services, launched today INVIEW ONCOPANEL, a comprehensive multigene cancer panel for solid tumour profiling.
The next-generation sequencing (NGS)-based panel consists of 50 cancer-specific genes that could add diagnostic, prognostic and therapeutic value to personalised care.
“INVIEW ONCOPANEL was the lone missing member of our cancer research and diagnostics portfolio,” said Dr Markus Benz, COO of GATC Biotech. “The service perfectly complements our liquid biopsy-based assay GATCLIQUID ONCOPANEL. It enables researchers and clinicians to screen not only liquid biopsy samples, but also tissue biopsy samples for genomic alterations. These carefully selected genes can help characterise a patient’s tumour and identify the most suitable treatment course on a case-by-case basis.”
With the rising need for validation of non-invasive liquid biopsies, researchers can now evaluate the concordance in mutation profiles from tumour tissue samples with INVIEW ONCOPANEL and from liquid biopsy samples with GATCLIQUID ONCOPANEL. Both cancer sets consist of more than 200 clinically actionable regions on 50 cancer-specific genes with strong predictive and prognostic potential. The targeted cancer-related genes include well-known tumour activators, tumour suppressors and biomarkers of drug resistance.
“By providing cost-efficient detection of mutations in key cancer drivers, we hope to draw the most meaningful molecular information out of invasive, but necessary tissue biopsies,” added Dr Benz. “With the ability to perform comparative studies on tumour tissue and plasma-based patient samples under diagnostic conditions, we also aim to contribute evidence to proof-of-concept studies that are needed to implement liquid biopsies in clinical settings.”
INVIEW ONCOPANEL, which is a standardised sample-to-data solution, applies proprietary protocols for low-input DNA extraction from precious formalin-fixed, paraffin-embedded (FFPE) or fresh tissue samples. Optimised workflows carried out on leading technologies consistently result in extraordinarily high sequence coverage, uniformity and sensitivity that are needed to profile solid tumours and support tailored treatment decisions with absolute confidence.
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
Designed by R-Tech Ueno, RU-101 ophthalmic solution is being trialled as a therapy for severe dry eye, for which no effective treatment is currently available. The recombinant human albumin is part of Novozymes Biopharma’s albumin range. Novozymes Biopharma has a strong reputation in the industry for helping customers in the safe and successful commercialization and approval of new products.
The prevalence of severe dry eye, where patients suffer from instability of the tear film, continues to increase. It is the most diagnosed of all ophthalmic disorders and estimates put the market at approximately 1.5 billion USD. The trials for RU-101 ophthalmic solution will move ahead in two stages, the first of which will assess safety using a placebo control, and allow confirmation of the maximum dose. The second stage will then use this maximum dose for 12 weeks to evaluate the safety and effectiveness of RU-101 ophthalmic solution.
Dermot Pearson, Marketing Director at Novozymes Biopharma said, “Novozymes is dedicated to supporting our customers in the drug development and testing stages, and in assisting with the optimisation of their pathways through regulatory approval procedures. We are therefore delighted that RU-101 ophthalmic solution has been approved for clinical testing.”
Novozymes Biopharma’s recombinant albumin is designed to provide quality performance benefits when included in drugs developed by our customers. It was selected as a key component of this novel therapy back in 2011, due to its proven high quality and enhanced safety profile. Animal-free, with an exceptional purity profile and convenient liquid format at room temperature, recombinant albumin delivers consistent levels of quality, leading to reduced lot testing and vendor auditing.
All Novozymes’ recombinant human albumins deliver stable, safe and regulatory compliant ingredients for drug delivery and formulation, and are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP).
TAP Biosystems installs CellBase CT system at PrimeCell to provide multiple Autologous Cell Therapies.
TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, is pleased to announce it is installing a system to automate the ex-vivo expansion of autologous cell therapies (CellBase CT™) at Czech-based firm PrimeCell, one of Central and Eastern Europe’s largest regenerative medicine companies.
The CellBase CT system at PrimeCell will be used in their new GMP facility at the National Tissue Centre Inc to rapidly scale up their manual cell culture processes in T-flasks and will provide a fully-contained aseptic cell expansion area. This will allow scientists to manufacture multiple autologous cell therapies from many individual patients in parallel and will enable the company to supply clients, including regional transplant centres in the Czech Republic, with a range of clean autologous therapies.
Dr Ralph von Strandmann, TAP Biosystems' European Sales Manager stated: “With EU funding for new technologies, there has been an increasing interest in manufacturing biotechnology products in Central and Eastern Europe. This has led progressive companies here to realise that utilising efficient methods of manufacturing cell therapies will provide them with a significant advantage in this competitive sector.”
Dr. von Strandmann added: “We are pleased that PrimeCell will be using CellBase CT to automate expansion of their autologous stem cell therapies. It is an excellent, cost-efficient alternative to labour intensive manual cell culture and could help make autologous cell therapies less expensive and more widely accessible to patients in Central and Eastern Europe.”
Molecular Devices®, market leader in microplate reader technology for over 25 years, has announced the launch of its SpectraMax® i3 Multi-Mode Detection Platform with SpectraMax® MiniMax® Imaging Cytometer.
The system is available as a stand-alone reader with the option for users to upgrade to additional applications and detection modes such as cellular imaging with the SpectraMax® MiniMax™ Imaging Cytometer, and cartridges for Time-Resolved Fluorescence, Fluorescence Polarization, and AlphaScreen® assays. The highly sensitive instrument accommodates the budget and throughput needs of both small and large laboratories alike.
The SpectraMax i3 Platform's base system features an integrated optical system enabling top and bottom reads for 6 - 384 well microplates and launches with three broad detection modes: luminescence, absorbance, and fluorescence. Patented user-exchangeable cartridge design expands the system's detection capability making it highly versatile, and able to offer application options far exceeding those of standard readers. The MiniMax Imaging Cytometer module adds first of its kind cellular imaging to a multi-mode detection platform, enabling fluorescence and bright field cellular imaging. Combining cellular imaging with microplate-based applications offers new ways for scientists to compress their workflows and increase efficiency.
Using a combination of a flash lamp for spectral flexibility and light emitting diodes (LEDs) for excitation power, Molecular Devices has developed the patent-pending Spectral FusionTM Illumination to deliver wavelength flexibility whilst maximizing signal strength, ultimately increasing overall performance.
Data from the SpectraMax i3 System is captured and analysed using Molecular Devices' proprietary, industry-leading SoftMax® Pro Software. The newly updated interface and Spectral Optimization Wizard simplifies the workflow and provides powerful data analysis features, eliminating the need for training on additional software. The SpectraMax i3 System is also available for use in GMP and GLP labs when used with the SoftMax® Pro 6.3 GxP Microplate Data Compliance Software.
Klaus Lun, Vice President of Product Marketing at Molecular Devices commented: "This new platform builds on Molecular Devices' experience in life science detection instrumentation development and our commitment to bring additional utility to the microplate reader, further compressing the workflows for our customers. With the MiniMax Imaging Cytometer for cellular imaging, Molecular Devices introduces a new world of cell-based assay application possibilities to the microplate reader. We will continue to expand the platform's functionality by adding new capabilities to the microplate reader through the introduction of application-specific detection cartridges in 2013."
The Oligo PRO™ 96XT system provides fast, automated and economical size-based purity analysis of single stranded DNA and RNA oligonucleotides, and double stranded RNA interference (RNAi) products.
This dedicated analyzer is capable of analyzing 96 different samples simultaneously by parallel capillary gel electrophoresis with on-line, fixed wavelength UV absorbance detection. Preloaded and optimized separation and capillary conditioning methods simplify and streamline operation. The system can perform unattended analysis of up to 288 samples at once. Application-specific data analysis software provides automated or manual peak integration. The Oligo PRO™ is a proven technology used every day worldwide in production and research labs.
Key Features of the Oligo PRO™ System Include:
Low cost per sample.Unsurpassed throughput for oligo purity analysis!
Size-based, single nucleotide resolution from 10-mer to 80-mer lengths.
Easy to use and maintain with a low cost of ownership.
Minimal sample preparation and consumption.
DNA oligonucleotide and RNA oligonucleotide analysis.
New, native gel analysis for measuring purity and annealing efficiency of dsRNAi products.
A full line of available reagents for "turn-key" operation.
Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
Humanized mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more